Maria V Christensen1, Claus Høgdall2, Steffen G Jensen1, Noor Lokman3, Carmela Ricciardelli3, Ib J Christensen1, Pernille Christiansen4, Julie Brask4, Mona A Karlsen2, Therese K Nissen5,6, Kirsten M Jochumsen5, Estrid Høgdall7. 1. Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. 2. Department of Gynaecology, Juliane Maria Centre (JMC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3. Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, Australia. 4. Department of Pathology, Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark. 5. Department of Gynaecology and Obstetrics, Odense University Hospital, University of Southern Denmark, Odense, Denmark. 6. Ditzel Group, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. 7. Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark estrid.hoegdall@regionh.dk.
Abstract
BACKGROUND/AIM: Ovarian cancer (OC) is the 5th most common cancer among European women. Approximately 70-80% of OC is diagnosed at advanced stage resulting in an elevated mortality rate. The aim of this study was to examine whether Annexin A2 and S100A10 expression can be used as prognostic markers for epithelial ovarian cancer (EOC). MATERIALS AND METHODS: Expression of Annexin A2 and S100A10 was evaluated in EOC tissue samples (n=303) by immunohistochemistry. The staining of the membrane, cytoplasmic and stroma was assessed according to intensity. RESULTS: The expression of both markers correlated to histological subtype, histological grading, International Federation of Gynecology and Obstetrics (FIGO) stage, and macro-radical surgery. Univariate Cox regression analysis showed that Annexin A2 and S100A10 in stromal tissue correlated with shorter overall survival (OS). Multivariate Cox regression analysis demonstrated no independent prognostic significance of stromal Annexin A2 expression. CONCLUSION: High expression of Annexin A2 and S100A10 in stromal tissue from EOC patients was associated with reduced OS; however, no independent prognostic value was found for any of the markers. Copyright
BACKGROUND/AIM: Ovarian cancer (OC) is the 5th most common cancer among European women. Approximately 70-80% of OC is diagnosed at advanced stage resulting in an elevated mortality rate. The aim of this study was to examine whether Annexin A2 and S100A10 expression can be used as prognostic markers for epithelial ovarian cancer (EOC). MATERIALS AND METHODS: Expression of Annexin A2 and S100A10 was evaluated in EOC tissue samples (n=303) by immunohistochemistry. The staining of the membrane, cytoplasmic and stroma was assessed according to intensity. RESULTS: The expression of both markers correlated to histological subtype, histological grading, International Federation of Gynecology and Obstetrics (FIGO) stage, and macro-radical surgery. Univariate Cox regression analysis showed that Annexin A2 and S100A10 in stromal tissue correlated with shorter overall survival (OS). Multivariate Cox regression analysis demonstrated no independent prognostic significance of stromal Annexin A2 expression. CONCLUSION: High expression of Annexin A2 and S100A10 in stromal tissue from EOC patients was associated with reduced OS; however, no independent prognostic value was found for any of the markers. Copyright
Authors: Przemyslaw Galazka; Lukasz Szylberg; Magdalena Bodnar; Jan Styczynski; Andrzej Marszalek Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Angela Diamantopoulou; Dimitrios Mantas; Ioannis D Kostakis; George Agrogiannis; Zoe Garoufalia; Nikolaos Kavantzas; Gregory Kouraklis Journal: In Vivo Date: 2020 Jan-Feb Impact factor: 2.155